These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15797585)

  • 1. Effects of non-contractile inclusions on mechanical performance of skeletal muscle.
    Drost MR; Hesselink RP; Oomens CW; van der Vusse GJ
    J Biomech; 2005 May; 38(5):1035-43. PubMed ID: 15797585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice.
    Hesselink RP; Gorselink M; Schaart G; Wagenmakers AJ; Kamphoven J; Reuser AJ; Van Der Vusse GJ; Drost MR
    Muscle Nerve; 2002 Jun; 25(6):873-83. PubMed ID: 12115977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-related decline in muscle strength and power output in acid 1-4 alpha-glucosidase knockout mice.
    Hesselink RP; Van Kranenburg G; Wagenmakers AJ; Van der Vusse GJ; Drost MR
    Muscle Nerve; 2005 Mar; 31(3):374-81. PubMed ID: 15674828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
    Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
    Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice.
    Hesselink RP; Schaart G; Wagenmakers AJ; Drost MR; van der Vusse GJ
    Muscle Nerve; 2006 Apr; 33(4):505-13. PubMed ID: 16372321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease.
    Rucker M; Fraites TJ; Porvasnik SL; Lewis MA; Zolotukhin I; Cloutier DA; Byrne BJ
    Development; 2004 Jun; 131(12):3007-19. PubMed ID: 15169761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors.
    Mah C; Cresawn KO; Fraites TJ; Pacak CA; Lewis MA; Zolotukhin I; Byrne BJ
    Gene Ther; 2005 Sep; 12(18):1405-9. PubMed ID: 15920463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice.
    Kiang A; Hartman ZC; Liao S; Xu F; Serra D; Palmer DJ; Ng P; Amalfitano A
    Mol Ther; 2006 Jan; 13(1):127-34. PubMed ID: 16169280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
    Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased muscle fatigability in GLUT-4-deficient mice.
    Gorselink M; Drost MR; de Brouwer KF; Schaart G; van Kranenburg GP; Roemen TH; van Bilsen M; Charron MJ; van der Vusse GJ
    Am J Physiol Endocrinol Metab; 2002 Feb; 282(2):E348-54. PubMed ID: 11788366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed or late-onset type II glycogenosis with globular inclusions.
    Sharma MC; Schultze C; von Moers A; Stoltenburg-Didinger G; Shin YS; Podskarbi T; Isenhardt K; Tews DS; Goebel HH
    Acta Neuropathol; 2005 Aug; 110(2):151-7. PubMed ID: 15986226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.
    Bijvoet AG; Van Hirtum H; Vermey M; Van Leenen D; Van Der Ploeg AT; Mooi WJ; Reuser AJ
    J Pathol; 1999 Nov; 189(3):416-24. PubMed ID: 10547605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse.
    Fuller M; Duplock S; Turner C; Davey P; Brooks DA; Hopwood JJ; Meikle PJ
    Anal Biochem; 2012 Feb; 421(2):759-63. PubMed ID: 22239964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active finite element analysis of skeletal muscle-tendon complex during isometric, shortening and lengthening contraction.
    Tsui CP; Tang CY; Leung CP; Cheng KW; Ng YF; Chow DH; Li CK
    Biomed Mater Eng; 2004; 14(3):271-9. PubMed ID: 15299239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.